# BridgeBio Pharma, Inc.: Form 8-K, filed Jul 2, 2025

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: 8-K
- Filed: 2025-07-02
- Accepted by EDGAR: Jul 1, 2025, 17:42 ET
- Period: 2025-06-27
- Accession: 0001140361-25-024413
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/ef20051467_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/ef20051467_8k.htm

Filed Jul 2, 2025.
Source: SEC EDGAR, the filing index for accession 0001140361-25-024413. Last ingested by Listed: Nov 12, 2026, 17:56 ET. No prices; not investment advice.
